Hep C Transplant Patients Benefit from New Therapy
the MPR take:
Liver transplant patients with recurring hepatitis C virus (HCV) have often experienced poor results from treatment, but a new study shows promise for effective therapy for this population. In data presented at the International Liver Congress 2014, 104 post-liver transplant patients with recurring HCV, poor clinical prognoses, and no remaining treatment options received sofosbuvir (SOF) and ribavirin (RBV) with pegylated interferon (PEG) (included at the doctors’ discretion) for >48 weeks. 62% had a sustained viral response after 12 weeks of treatment (SVR12) and 62% of patients saw improvement in clinical conditions associated with hepatic decompensation and/or benefits in liver function tests.
READ FULL ARTICLE From virtualpressoffice.easl.eu